Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» OPuS-2
OPuS-2
8 Major Biopharma Events Coming Later in 2016 and in 2017
24/7 Wall St
Tue, 03/29/16 - 10:33 pm
Vertex Pharmaceuticals
VX-661
cystic fibrosis
Incyte
ruxolitinib
colorectal cancer
breast cancer
Ultragenyx
KRN23
osteomalacia
GW Pharma
Epidiolex
Puma Biotechnology
neratinib
Celator Pharmaceuticals
Vyxeos
Biocryst
OPuS-2
BCX7353
HAE
Galena Biopharma
NeuVax
trastuzumab
4 Key FDA Decisions Expected By Year End
24/7 Wall St
Sun, 11/29/15 - 12:43 pm
FDA
Achillion
hepatitis C
Biocryst
OPuS-2
BCX4161
Tetraphase Pharmaceuticals
Lucitanib
Clovis Oncology
4 Key FDA Decisions Expected in November and December
24/7 Wall St
Sun, 11/1/15 - 11:18 am
FDA
Androxal
Repros Therapeutics
elvitegravir
cobicistat
emtricitabine
tenofovir alafenamide
OPuS-2
Biocryst
Synergy Pharmaceuticals
plecanatide
